Mass spectrometry imaging (MSI) is emerging as a powerful analytical tool for detection,
quantification, and simultaneous spatial molecular imaging of endogenous and exogenous …

Tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) have
dramatically improved progression-free survival in non-small-cell lung cancer (NSCLC) …

Mass spectrometry imaging (MSI) is a powerful technique that reveals the spatial distribution
of various molecules in biological samples, and it is widely used in pathology‐related …

Mass spectrometry imaging (MSI) is an enabling technology for label-free drug disposition
studies at high spatial resolution in life science-and pharmaceutical research. We present …

Because of the heterogeneity and complexity of tumor structure, cancer drugs often cannot
effectively reach the tumor, which is one of the reasons for drug resistance and treatment …

Mass spectrometry imaging (MSI) has seen remarkable development in recent years. The
possibility of getting quantitative or semiquantitative data, while maintaining the spatial …

Failure of systemic cancer treatment can be, at least in part, due to the drug not being
delivered to the tumour at sufficiently high concentration and/or sufficiently homogeneous …

In this two-part review we present an up-to-date description of different imaging methods
available to map the localization of drugs on skin as a complement of established ex-vivo …

Spatial mapping of heterogeneity in gene expression in cancer tissues can improve our
understanding of cancers and help in the rapid detection of cancers with high accuracy and …

Patient-derived xenografts (PDX) can adequately reflect clinical drug efficacy. However, the
methods for evaluating drug efficacy are not fully established. We selected five non–small …